Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Widespread resistance to common antibiotics is increasing: WHO

Increasing resistance to essential antibiotics poses a growing threat to global health, with one...

Dopamine helps our brains to let go of memories

In a discovery that could reshape how we think about memory, researchers at Flinders University...

Vaccine for elephant herpesvirus found to be safe

The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...

Content from other channels on our network

New PROeco II power supplies from Weidmüller: Built for reliability and scale

Pure Dairy opens manufacturing plant in Dandenong South

Siemens and NVIDIA preview technology for AI-era manufacturing

Lynas to expand heavy rare earths separation facility in Malaysia

Li-S Energy announces Australia’s first lithium foil production line

Report explores Australian perceptions of Medtech access

Vertical healing: redefining health care through high-rise hospital design

Using better network insight to boost productivity in Australian health care

Construction underway on new Redcliffe cancer care centre

Digital health lessons across industries

Seifert Systems Outdoor Series (OC): Precision Cooling for Enclosures in Outdoor Environments

The Inside Scoop: How Fishbowl Boosted Lick Ice Cream's Sweet Success

Bringing the benefits of PCR and automation to high-throughput beverage testing, with the SureTect Automation Platform

Complete snack and confectionery line on show

$340,000 safety spend after fruit packing injury